Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Markaki

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Cancer Letters|February 24, 2007
The prognostic value of the topographic distribution of uPAR expression in invasive breast carcinomasI Giannopoulou, E Mylona, A Kapranou, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 30, 2006
Clinicopathological and prognostic significance of vascular endothelial growth factors (VEGF)-C and -D and VEGF receptor 3 in invasive breast carcinomaE Mylona, P Alexandrou, A Mpakali, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|November 25, 2003
The favorable prognostic impact of tissue inhibitor of matrix metalloproteinases-1 protein overexpression in breast cancer cellsL Nakopoulou, I Giannopoulou, A Ch Lazaris, et al.
European Journal of Gynaecological Oncology|March 23, 2004
The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapyA Protopapas, E Diakomanolis, A Bamias, et al.
Mutation Research|February 4, 2010
Low frequency of somatic mutations in uterine sarcomas: a molecular analysis and review of the literatureS Murray, H Linardou, G Mountzios, et al.
European Journal of Gynaecological Oncology|January 10, 2006
Adjuvant chemotherapy with paclitaxel and carboplatin in non-endometrioid carcinoma of the uterusG T Bozas, A Bamias, E Kastritis, et al.
European Journal of Gynaecological Oncology|September 19, 2009
Clinicopathological features of primary fallopian tube carcinoma: a single institution experienceC A Papadimitriou, S Markaki, E Lianos, et al.
European Journal of Gynaecological Oncology|May 8, 2007
Anthracycline-based adjuvant chemotherapy in early-stage uterine sarcomas: long-term results of a single institution experienceC A Papadimitriou, M P Zorzou, S Markaki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 14, 2006
Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapyV Malamou-Mitsi, H Gogas, U Dafni, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Cancer Letters|February 24, 2007
The prognostic value of the topographic distribution of uPAR expression in invasive breast carcinomasI Giannopoulou, E Mylona, A Kapranou, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 30, 2006
Clinicopathological and prognostic significance of vascular endothelial growth factors (VEGF)-C and -D and VEGF receptor 3 in invasive breast carcinomaE Mylona, P Alexandrou, A Mpakali, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|November 25, 2003
The favorable prognostic impact of tissue inhibitor of matrix metalloproteinases-1 protein overexpression in breast cancer cellsL Nakopoulou, I Giannopoulou, A Ch Lazaris, et al.
European Journal of Gynaecological Oncology|March 23, 2004
The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapyA Protopapas, E Diakomanolis, A Bamias, et al.
Mutation Research|February 4, 2010
Low frequency of somatic mutations in uterine sarcomas: a molecular analysis and review of the literatureS Murray, H Linardou, G Mountzios, et al.
European Journal of Gynaecological Oncology|January 10, 2006
Adjuvant chemotherapy with paclitaxel and carboplatin in non-endometrioid carcinoma of the uterusG T Bozas, A Bamias, E Kastritis, et al.
European Journal of Gynaecological Oncology|September 19, 2009
Clinicopathological features of primary fallopian tube carcinoma: a single institution experienceC A Papadimitriou, S Markaki, E Lianos, et al.
European Journal of Gynaecological Oncology|May 8, 2007
Anthracycline-based adjuvant chemotherapy in early-stage uterine sarcomas: long-term results of a single institution experienceC A Papadimitriou, M P Zorzou, S Markaki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 14, 2006
Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapyV Malamou-Mitsi, H Gogas, U Dafni, et al.
Pageof 4